Compounding Chemotherapy Market Research Report - Forecast till 2027

Compounding Chemotherapy Market: Information By Dose (Chemotherapeutic and Non-Chemotherapeutics), By Compounding Type (Pharmaceutical Ingredient Alteration (PIA), Currently Unavailable Pharmaceutical Manufacturing (CUPM), Pharmaceutical Dosage Alteration), By Delivery Method (Gravimetric Automated Compounding Device (Weight-Based) and Volumetric Automated Compounding Device (Volume-Based)), By Sterility (Sterile and Non-Sterile), By Technology (With Robotic Arms and Without Robotic Arms), By Compounder Type (Pharmoduct, Equashield Pro,...

ID: MRFR/HC/8901-CR | December 2020 | Region: Global | 193 Pages         

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION 21

2.2 SCOPE OF THE STUDY 21

2.3 RESEARCH OBJECTIVE 21

2.4 MARKET STRUCTURE 22

2.5 ASSUMPTIONS & LIMITATIONS 23

3 RESEARCH METHODOLOGY

3.1 DATA MINING 24

3.2 SECONDARY RESEARCH 25

3.3 PRIMARY RESEARCH 26

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 27

3.5 FORECASTING TECHNIQUES 28

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 29

3.6.1 BOTTOM-UP APPROACH 30

3.6.2 TOP-DOWN APPROACH 30

3.7 DATA TRIANGULATION 31

3.8 VALIDATION 31

4 MARKET DYNAMICS

4.1 OVERVIEW 32

4.2 DRIVERS 33

4.2.1 TECHNOLOGICAL DEVELOPMENTS AND GROUND-BREAKING TECHNIQUES 33

4.2.2 INCREASE IN DRUGS SHORTAGE COMPRISING CANCER MEDICINES 34

4.2.3 RISE IN AWARENESS AND ADAPTATION OF NEW TECHNOLOGIES AMONG CANCER HOSPITALS 34

4.2.4 RISING PREVALENCE OF CANCER PATIENTS 34

4.3 RESTRAINTS 36

4.3.1 DEARTH OF PRACTICED PHARMACISTS AND LAB TECHNICIANS 36

4.4 OPPORTUNITIES 36

4.4.1 NEW PRODUCT INNOVATIONS 36

4.4.2 RISE IN PARTNERSHIPS & COLLABORATIONS 36

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS 37

5.1.1 R&D AND DESIGNING 37

5.1.2 MANUFACTURING 38

5.1.3 DISTRIBUTION & SALES 38

5.1.4 POST SALES SERVICES 38

5.2 PORTER’S FIVE FORCES MODEL 38

5.2.1 BARGAINING POWER OF SUPPLIERS 39

5.2.2 BARGAINING POWER OF BUYERS 39

5.2.3 THREAT OF NEW ENTRANTS 39

5.2.4 THREAT OF SUBSTITUTES 40

5.2.5 INTENSITY OF RIVALRY 40

5.3 COVID-19 IMPACT ANALYSIS 40

5.3.1 IMPACT ON SUPPLY CHAIN 41

5.3.2 IMPACT ON PRODUCTION 41

5.3.3 IMPACT ON REGIONS 41

5.3.4 DEMAND-SUPPLY GAP ANALYSIS 41

5.4 LIST OF POTENTIAL CUSTOMERS 42

6 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE

6.1 OVERVIEW 45

6.2 CHEMOTHERAPEUTIC 46

6.3 NON-CHEMOTHERAPEUTICS 46

7 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE

7.1 OVERVIEW 47

7.2 PHARMACEUTICAL INGREDIENT ALTERATION (PIA) 48

7.3 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING (CUPM) 49

7.4 PHARMACEUTICAL DOSAGE ALTERATION (PDA) 50

8 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD

8.1 OVERVIEW 51

8.2 GRAVIMETRIC AUTOMATED COMPOUNDING DEVICE (WEIGHT-BASED) 52

8.3 VOLUMETRIC AUTOMATED COMPOUNDING DEVICE (VOLUME-BASED) 53

9 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY

9.1 OVERVIEW 54

9.2 STERILE 55

9.3 NON-STERILE 56

10 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY

10.1 OVERVIEW 57

10.2 WITH ROBOTIC ARMS 58

10.3 WITHOUT ROBOTIC ARMS 59

11 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE

11.1 OVERVIEW 60

11.2 PHARMODUCT 61

11.3 EQUASHIELD PRO 61

11.4 MEDIMIX 61

11.5 INTEGRA 61

11.6 OTHERS 61

12 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION

12.1 OVERVIEW 62

12.2 BREAST CANCER 63

12.3 BLOOD CANCER 64

12.4 PROSTATE CANCER 65

12.5 GASTROINTESTINAL CANCER 66

12.6 RESPIRATORY/LUNG CANCER 66

12.7 OTHERS 67

13 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY REGION

13.1 OVERVIEW 68

13.2 AMERICAS 69

13.2.1 NORTH AMERICA 73

13.2.1.1 US 76

13.2.1.2 CANADA 79

13.2.2 LATIN AMERICA 82

13.2.2.1 BRAZIL 85

13.2.2.2 REST OF LATIN AMERICA 88

13.3 EUROPE 92

13.3.1 WESTERN EUROPE 96

13.3.1.1 GERMANY 99

13.3.1.2 FRANCE 102

13.3.1.3 UK 105

13.3.1.4 ITALY 108

13.3.1.5 SPAIN 111

13.3.1.6 REST OF WESTERN EUROPE 114

13.3.2 EASTERN EUROPE 117

13.4 ASIA-PACIFIC 121

13.4.1 CHINA 125

13.4.2 JAPAN 127

13.4.3 INDIA 130

13.4.4 AUSTRALIA 133

13.4.5 SOUTH KOREA 136

13.4.6 REST OF ASIA-PACIFIC 139

13.5 MIDDLE EAST & AFRICA 142

13.5.1 MIDDLE EAST 145

13.5.2 AFRICA 148

14 COMPETITIVE LANDSCAPE

14.1 OVERVIEW 151

14.2 COMPETITOR DASHBOARD 152

14.3 MAJOR GROWTH STRATEGY IN THE GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 153

14.4 MARKET SHARE ANALYSIS 153

14.5 COMPETITIVE BENCHMARKING 154

14.6 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 155

14.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 156

14.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 156

14.8.1 ACQUISITION 156

14.8.2 COLLABORATION 156

14.8.3 PARTNERSHIP 157

14.8.4 COLLABORATION 157

15 COMPANY PROFILE

15.1 B. BRAUN MELSUNGEN AG 158

15.1.1 COMPANY OVERVIEW 158

15.1.2 FINANCIAL OVERVIEW 158

15.1.3 PRODUCTS/SERVICES OFFERED 159

15.1.4 KEY DEVELOPMENTS 159

15.1.5 SWOT ANALYSIS 160

15.1.6 KEY STRATEGIES 160

15.2 PFIZER INC. 161

15.2.1 COMPANY OVERVIEW 161

15.2.2 FINANCIAL OVERVIEW 161

15.2.3 PRODUCTS/SERVICES OFFERED 162

15.2.4 KEY DEVELOPMENTS 162

15.2.5 SWOT ANALYSIS 162

15.2.6 KEY STRATEGIES 163

15.3 BAXTER 164

15.3.1 COMPANY OVERVIEW 164

15.3.2 FINANCIAL OVERVIEW 164

15.3.3 PRODUCTS/SERVICES OFFERED 165

15.3.4 KEY DEVELOPMENTS 165

15.3.5 SWOT ANALYSIS 165

15.3.6 KEY STRATEGIES 166

15.4 GRIFOLS, S.A. 167

15.4.1 COMPANY OVERVIEW 167

15.4.2 FINANCIAL OVERVIEW 167

15.4.3 PRODUCTS/SERVICES OFFERED 168

15.4.4 KEY DEVELOPMENTS 168

15.4.5 SWOT ANALYSIS 168

15.4.6 KEY STRATEGIES 169

15.5 THE METRIX COMPANY 170

15.5.1 COMPANY OVERVIEW 170

15.5.2 FINANCIAL OVERVIEW 170

15.5.3 PRODUCTS/SERVICES OFFERED 170

15.5.4 KEY DEVELOPMENTS 170

15.5.5 SWOT ANALYSIS 171

15.5.6 KEY STRATEGIES 171

15.6 ADDED PHARMA 172

15.6.1 COMPANY OVERVIEW 172

15.6.2 FINANCIAL OVERVIEW 172

15.6.3 PRODUCTS/SERVICES OFFERED 172

15.6.4 KEY DEVELOPMENTS 173

15.6.5 SWOT ANALYSIS 173

15.6.6 KEY STRATEGIES 173

15.7 EQUASHIELD 174

15.7.1 COMPANY OVERVIEW 174

15.7.2 FINANCIAL OVERVIEW 174

15.7.3 PRODUCTS/SERVICES OFFERED 174

15.7.4 KEY DEVELOPMENTS 174

15.7.5 SWOT ANALYSIS 175

15.7.6 KEY STRATEGIES 175

15.8 MILLERS PHARMACY 176

15.8.1 COMPANY OVERVIEW 176

15.8.2 FINANCIAL OVERVIEW 176

15.8.3 PRODUCTS/SERVICES OFFERED 176

15.8.4 KEY DEVELOPMENTS 176

15.8.5 SWOT ANALYSIS 177

15.8.6 KEY STRATEGIES 177

15.9 COMECER S.P.A. 178

15.9.1 COMPANY OVERVIEW 178

15.9.2 FINANCIAL OVERVIEW 178

15.9.3 PRODUCTS/SERVICES OFFERED 178

15.9.4 SWOT ANALYSIS 179

15.9.5 KEY STRATEGIES 179

15.10 OMNICELL 180

15.10.1 COMPANY OVERVIEW 180

15.10.2 FINANCIAL OVERVIEW 180

15.10.3 PRODUCTS/SERVICES OFFERED 180

15.10.4 SWOT ANALYSIS 181

15.10.5 KEY STRATEGIES 181

15.11 ICON GROUP 182

15.11.1 COMPANY OVERVIEW 182

15.11.2 FINANCIAL OVERVIEW 182

15.11.3 PRODUCTS/SERVICES OFFERED 182

15.11.4 KEY DEVELOPMENTS 183

15.11.5 SWOT ANALYSIS 184

15.11.6 KEY STRATEGIES 184

15.12 DEDALUS GROUP 185

15.12.1 COMPANY OVERVIEW 185

15.12.2 FINANCIAL OVERVIEW 185

15.12.3 PRODUCTS/SERVICES OFFERED 185

15.12.4 KEY DEVELOPMENTS 185

15.12.5 SWOT ANALYSIS 186

15.12.6 KEY STRATEGIES 186

15.13 ARXIUM 187

15.13.1 COMPANY OVERVIEW 187

15.13.2 FINANCIAL OVERVIEW 187

15.13.3 PRODUCTS/SERVICES OFFERED 187

15.13.4 KEY DEVELOPMENTS 187

15.13.5 SWOT ANALYSIS 188

15.13.6 KEY STRATEGIES 188

15.14 STERILINE S.R.L. 189

15.14.1 COMPANY OVERVIEW 189

15.14.2 FINANCIAL OVERVIEW 189

15.14.3 PRODUCTS/SERVICES OFFERED 189

15.14.4 KEY DEVELOPMENTS 189

15.14.5 SWOT ANALYSIS 190

15.14.6 KEY STRATEGIES 190

15.15 LOCCIONI 191

15.15.1 COMPANY OVERVIEW 191

15.15.2 PRODUCTS/SERVICES OFFERED 191

15.15.3 KEY DEVELOPMENTS 191

15.15.4 SWOT ANALYSIS 192

15.15.5 KEY STRATEGIES 192

16 APPENDIX

16.1 REFERENCES 193

16.2 RELATED REPORTS 193

17 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 23

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 26

TABLE 3 LIST OF POTENTIAL CUSTOMERS FOR GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 42

TABLE 1 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 45

TABLE 2 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR CHEMOTHERAPEUTIC, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 3 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR NON-CHEMOTHERAPEUTICS, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 4 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 48

TABLE 5 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION (PIA),

BY REGION, 2020–2027 (USD MILLION) 48

TABLE 6 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING,

BY REGION, 2020–2027 (USD MILLION) 49

TABLE 7 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION,

BY REGION, 2020–2027 (USD MILLION) 50

TABLE 8 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 52

TABLE 9 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR GRAVIMETRIC AUTOMATED COMPOUNDING DEVICE,

BY REGION, 2020–2027 (USD MILLION) 52

TABLE 10 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR VOLUMETRIC AUTOMATED COMPOUNDING DEVICE,

BY REGION, 2020–2027 (USD MILLION) 53

TABLE 11 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 54

TABLE 12 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR STERILE, BY REGION, 2020–2027 (USD MILLION) 55

TABLE 13 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR NON-STERILE, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 14 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 57

TABLE 15 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY REGION, 2020–2027 (USD MILLION) 58

TABLE 16 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 17 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR WITHOUT ROBOTIC ARMS, BY REGION, 2020–2027 (USD MILLION) 59

TABLE 18 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 60

TABLE 19 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 63

TABLE 20 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION) 63

TABLE 21 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR BLOOD CANCER, BY REGION, 2020–2027 (USD MILLION) 64

TABLE 22 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION) 65

TABLE 23 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR GASTROINTESTINAL CANCER, BY REGION, 2020–2027 (USD MILLION) 66

TABLE 24 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR RESPIRATORY/LUNG CANCER, BY REGION, 2020–2027 (USD MILLION) 66

TABLE 25 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET FOR OTHER CANCER APPLICATIONS,

BY REGION, 2020–2027 (USD MILLION) 67

TABLE 26 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 68

TABLE 27 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 69

TABLE 28 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 70

TABLE 29 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 70

TABLE 30 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 71

TABLE 31 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 71

TABLE 32 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 71

TABLE 33 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 34 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 72

TABLE 35 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 72

TABLE 36 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73

TABLE 37 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 73

TABLE 38 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 74

TABLE 39 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 74

TABLE 40 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 74

TABLE 41 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 75

TABLE 42 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 43 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 75

TABLE 44 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 76

TABLE 45 US COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 76

TABLE 46 US COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 77

TABLE 47 US COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 77

TABLE 48 US COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 78

TABLE 49 US COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 78

TABLE 50 US COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 51 US COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 79

TABLE 52 US COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 79

TABLE 53 CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 79

TABLE 54 CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 80

TABLE 55 CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 80

TABLE 56 CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 80

TABLE 57 CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 81

TABLE 58 CANADA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 59 CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 81

TABLE 60 CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 82

TABLE 61 LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COUNTRY/REGION, 2020–2027 (USD MILLION) 82

TABLE 62 LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 82

TABLE 63 LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 83

TABLE 64 LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 83

TABLE 65 LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 83

TABLE 66 LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 84

TABLE 67 LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 68 LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 84

TABLE 69 LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85

TABLE 70 BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 85

TABLE 71 BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 86

TABLE 72 BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 86

TABLE 73 BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 86

TABLE 74 BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 87

TABLE 75 BRAZIL COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 76 BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 87

TABLE 77 BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88

TABLE 78 REST OF LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 88

TABLE 79 REST OF LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 89

TABLE 80 REST OF LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 89

TABLE 81 REST OF LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 89

TABLE 82 REST OF LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 90

TABLE 83 REST OF LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 84 REST OF LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 90

TABLE 85 REST OF LATIN AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91

TABLE 86 EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 92

TABLE 87 EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 93

TABLE 88 EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 93

TABLE 89 EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 93

TABLE 90 EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 94

TABLE 91 EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 94

TABLE 92 EUROPE COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 93 EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 95

TABLE 94 EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95

TABLE 95 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 96

TABLE 96 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 97

TABLE 97 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 97

TABLE 98 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 97

TABLE 99 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 98

TABLE 100 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 98

TABLE 101 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 102 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 99

TABLE 103 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99

TABLE 104 GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 99

TABLE 105 GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 100

TABLE 106 GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 100

TABLE 107 GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 100

TABLE 108 GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 101

TABLE 109 GERMANY COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 110 GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 101

TABLE 111 GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 102

TABLE 112 FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 102

TABLE 113 FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 103

TABLE 114 FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 103

TABLE 115 FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 103

TABLE 116 FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 104

TABLE 117 FRANCE COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 118 FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 104

TABLE 119 FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 105

TABLE 120 UK COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 105

TABLE 121 UK COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 106

TABLE 122 UK COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 106

TABLE 123 UK COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 106

TABLE 124 UK COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 107

TABLE 125 UK COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 126 UK COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 107

TABLE 127 UK COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 108

TABLE 128 ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 108

TABLE 129 ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 109

TABLE 130 ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 109

TABLE 131 ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 109

TABLE 132 ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 110

TABLE 133 ITALY COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 110

TABLE 134 ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 110

TABLE 135 ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 111

TABLE 136 SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 111

TABLE 137 SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 112

TABLE 138 SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 112

TABLE 139 SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 112

TABLE 140 SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 113

TABLE 141 SPAIN COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 142 SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 113

TABLE 143 SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114

TABLE 144 REST OF WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 114

TABLE 145 REST OF WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 115

TABLE 146 REST OF WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 115

TABLE 147 REST OF WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 115

TABLE 148 REST OF WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 116

TABLE 149 REST OF WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS,

BY TYPE, 2020–2027 (USD MILLION) 116

TABLE 150 REST OF WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 116

TABLE 151 REST OF WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 117

TABLE 152 EASTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 117

TABLE 153 EASTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 118

TABLE 154 EASTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 118

TABLE 155 EASTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 118

TABLE 156 EASTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 119

TABLE 157 EASTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 119

TABLE 158 EASTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 119

TABLE 159 EASTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 120

TABLE 160 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 121

TABLE 161 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 122

TABLE 162 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 122

TABLE 163 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 123

TABLE 164 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 123

TABLE 165 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 123

TABLE 166 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 124

TABLE 167 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 124

TABLE 168 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124

TABLE 169 CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 125

TABLE 170 CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 125

TABLE 171 CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 125

TABLE 172 CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 126

TABLE 173 CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 126

TABLE 174 CHINA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 126

TABLE 175 CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 127

TABLE 176 CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 127

TABLE 177 JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 127

TABLE 178 JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 128

TABLE 179 JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 128

TABLE 180 JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 128

TABLE 181 JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 129

TABLE 182 JAPAN COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 129

TABLE 183 JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 129

TABLE 184 JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130

TABLE 185 INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 130

TABLE 186 INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 131

TABLE 187 INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 131

TABLE 188 INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 131

TABLE 189 INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 132

TABLE 190 INDIA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 132

TABLE 191 INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 132

TABLE 192 INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 133

TABLE 193 AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 133

TABLE 194 AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 134

TABLE 195 AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 134

TABLE 196 AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 134

TABLE 197 AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 135

TABLE 198 AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 135

TABLE 199 AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 135

TABLE 200 AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 136

TABLE 201 SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 136

TABLE 202 SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 137

TABLE 203 SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 137

TABLE 204 SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 137

TABLE 205 SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 138

TABLE 206 SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 138

TABLE 207 SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 138

TABLE 208 SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139

TABLE 209 REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 139

TABLE 210 REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 139

TABLE 211 REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 140

TABLE 212 REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 140

TABLE 213 REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 140

TABLE 214 REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 141

TABLE 215 REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 141

TABLE 216 REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 141

TABLE 217 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 142

TABLE 218 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 143

TABLE 219 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 143

TABLE 220 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 143

TABLE 221 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 144

TABLE 222 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 144

TABLE 223 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027

(USD MILLION) 144

TABLE 224 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 145

TABLE 225 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145

TABLE 226 MIDDLE EAST COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 145

TABLE 227 MIDDLE EAST COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 146

TABLE 228 MIDDLE EAST COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 146

TABLE 229 MIDDLE EAST COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 146

TABLE 230 MIDDLE EAST COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 147

TABLE 231 MIDDLE EAST COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 147

TABLE 232 MIDDLE EAST COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 147

TABLE 233 MIDDLE EAST COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 148

TABLE 234 AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020–2027 (USD MILLION) 148

TABLE 235 AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2020–2027 (USD MILLION) 148

TABLE 236 AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 149

TABLE 237 AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2020–2027 (USD MILLION) 149

TABLE 238 AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 149

TABLE 239 AFRICA COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARMS, BY TYPE, 2020–2027 (USD MILLION) 150

TABLE 240 AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE, 2020–2027 (USD MILLION) 150

TABLE 241 AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150

TABLE 242 COMPETITOR DASHBOARD: GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 152

TABLE 243 THE MOST ACTIVE PLAYER IN THE GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 155

TABLE 244 ACQUISITION 156

TABLE 245 COLLABORATION 156

TABLE 246 PARTNERSHIP 157

TABLE 247 COLLABORATION 157

TABLE 248 B BRAUN MELSUNGEN AG: PRODUCTS/SERVICES OFFERED 159

TABLE 249 PFIZER INC.: PRODUCTS/SERVICES OFFERED 162

TABLE 250 BAXTER: PRODUCTS/SERVICES OFFERED 165

TABLE 251 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED 168

TABLE 252 THE METRIX COMPANY PRODUCTS/SERVICES OFFERED 170

TABLE 253 ADDED PHARMA: PRODUCTS/SERVICES OFFERED 172

TABLE 254 EQUASHILED: PRODUCTS/SERVICES OFFERED 174

TABLE 255 EQUASHIELD: KEY DEVELOPMENTS 174

TABLE 256 MILLERS PHARMACY: PRODUCTS/SERVICES OFFERED 176

TABLE 257 COMECER S.P.A.: PRODUCTS/SERVICES OFFERED 178

TABLE 258 KEY DEVELOPMENTS 178

TABLE 259 OMNICELL.: PRODUCTS/SERVICES OFFERED 180

TABLE 260 KEY DEVELOPMENTS 181

TABLE 261 ICON GROUP: PRODUCTS/SERVICES OFFERED 182

TABLE 262 ICON GROUP: KEY DEVELOPMENTS 183

TABLE 263 DEDALUS GROUP: PRODUCTS/SERVICES OFFERED 185

TABLE 264 DEDALUS GROUP: KEY DEVELOPMENTS 185

TABLE 265 ARXIUM: PRODUCTS/SERVICES OFFERED 187

TABLE 266 STERILINE S.R.L.: PRODUCTS/SERVICES OFFERED 189

TABLE 267 LOCCIONI: PRODUCTS/SERVICES OFFERED 191

18 LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 20

FIGURE 2 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 22

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 29

FIGURE 4 MARKET DYNAMICS: COMPOUNDING CHEMOTHERAPY MARKET 33

FIGURE 5 DRIVER IMPACT ANALYSIS 35

FIGURE 6 RESTRAINT IMPACT ANALYSIS 36

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 37

FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 39

FIGURE 9 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE, 2020 & 2027 (USD MILLION) 45

FIGURE 10 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, COMPOUNDING TYPE, 2020 & 2027 (USD MILLION) 47

FIGURE 11 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, DELIVERY METHOD, 2020 & 2027 (USD MILLION) 51

FIGURE 12 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, STERILITY, 2020 & 2027 (USD MILLION) 54

FIGURE 13 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, TECHNOLOGY, 2020 & 2027 (USD MILLION) 57

FIGURE 14 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, COMPOUNDER TYPE, 2020 & 2027 (USD MILLION) 60

FIGURE 15 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, APPLICATION, 2020 & 2027 (USD MILLION) 62

FIGURE 16 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY REGION, 2020 & 2027 (USD MILLION) 68

FIGURE 17 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET SHARE, BY REGION, 2020 (%) 69

FIGURE 18 AMERICAS COMPOUNDING CHEMOTHERAPY MARKET SHARE, BY REGION, 2020 (%) 70

FIGURE 19 NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET SHARE, BY COUNTRY, 2020 (%) 73

FIGURE 20 EUROPE COMPOUNDING CHEMOTHERAPY MARKET SHARE, BY REGION 2020 (%) 92

FIGURE 21 WESTERN EUROPE COMPOUNDING CHEMOTHERAPY MARKET SHARE, BY COUNTRY, 2020 (%) 96

FIGURE 22 ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET SHARE, BY COUNTRY, 2020 (%) 122

FIGURE 23 MIDDLE EAST & AFRICA COMPOUNDING CHEMOTHERAPY MARKET SHARE, BY REGION, 2020 (%) 142

FIGURE 24 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 153

FIGURE 25 MAJOR MANUFACTURERS MARKET SHARE ANALYSIS, 2020 (%) 153

FIGURE 26 BENCHMARKING OF MAJOR COMPETITORS 154

FIGURE 27 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, KEY DEVELOPMENTS & GROWTH STRATEGIES (%) 156

FIGURE 28 B BRAUN MELSUNGEN AG: FINANCIAL OVERVIEW SNAPSHOT 158

FIGURE 29 B BRAUN MELSUNGEN AG: SWOT ANALYSIS 160

FIGURE 30 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 161

FIGURE 31 PFIZER INC: SWOT ANALYSIS 162

FIGURE 32 BAXTER: FINANCIAL OVERVIEW SNAPSHOT 164

FIGURE 33 BAXTER: SWOT ANALYSIS 165

FIGURE 34 GRIFOLS, S.A.: FINANCIAL OVERVIEW SNAPSHOT 167

FIGURE 35 GRIFOLS, S.A.: SWOT ANALYSIS 168

FIGURE 36 THE METRIX COMPANY.: SWOT ANALYSIS 171

FIGURE 37 ADDED PHARMA: SWOT ANALYSIS 173

FIGURE 38 EQUASHIELD: SWOT ANALYSIS 175

FIGURE 39 MILLERS PHARMACY: SWOT ANALYSIS 177

FIGURE 40 COMECER S.P.A.: FINANCIAL OVERVIEW SNAPSHOT 178

FIGURE 41 COMECER S.P.A CORP.: SWOT ANALYSIS 179

FIGURE 42 OMNICELL.: FINANCIAL OVERVIEW SNAPSHOT 180

FIGURE 43 OMNICELL.: SWOT ANALYSIS 181

FIGURE 44 ICON GROUP: SWOT ANALYSIS 184

FIGURE 45 DEDALUS GROUP: SWOT ANALYSIS 186

FIGURE 46 ARXIUM: SWOT ANALYSIS 188

FIGURE 47 STERILINE S.R.L.: SWOT ANALYSIS 190

FIGURE 48 LOCCIONI: SWOT ANALYSIS 192

Compounding Chemotherapy Market

Global Compounding Chemotherapy Market is estimated to reach USD 523.99 Million at a CAGR of 6.29% over the forecast period (2022 – 2030).

Segmentation

By Dose Chemotherapeutic And Non Chemotherapeutics
By Delivery Method Gravimetric Automated Compounding Device Volumetric Automated Compounding Device
By Sterility Sterile And Non Sterile
By Technology With Robotic Arms And Without Robotic Arms

Key Players

  • Braun Melsungen AG
  • Pfizer Inc.
  • Baxter
  • Grifols SA
  • The Metrix Company
  • Added Pharma
  • Equashield
  • Millers Pharmacy

Drivers

  • Technical Advances
  • Cutting-Edge Strategies\r\n
Speak to Analyst Request a Free Sample

Compounding Chemotherapy Market Analysis


The compounding chemotherapy market is showing significant growth. Compounding of drugs makes them patient-specific which is the biggest advantage. Compounding chemotherapy can minimize the risk of underdose or overdose of drugs for a patient. Therefore, owing to its numerous advantages. 


There is a substantial rise in the incidence of diseases such as cancer, bone marrow diseases, immunity disorders, etc. which require chemotherapy treatment. An increase in pollution levels and rising incidence of such diseases are generating demand for compounding chemotherapy. The market is estimated to grow at a CAGR ( Compound Annual Growth Rate ) of 6.04 % over the current forecast period ( 2020-2027 ). 


Compounding requires expertise, only the best professionals can perform it. However, with the advent of technology, automated compounding devices are bringing a change in the market. Moreover, the market will see a new dawn, if regulatory authorities start verifying the effectiveness of compounded drugs. The valuation of the compounding chemotherapy market is expected to reach USD 635.58 Million by the end of the forecast period in 2027.  


Covid-19 analysis


Covid 19 had a huge impact on the drug production and delivery market. The reluctance of patients to approach hospitals and clinics,  owing to virus fear, caused a decline in demand. Hence, the overall production was down.  


Compounding chemotherapy requires many drug formations but due to supply chain disruptions, there was a halt in production. The restrictions on the movement of goods and people had a severe impact on the market. However,  government support received by the pharmaceutical industry during the period is boosting the growth. The market is expected to catch the earlier growth rate very soon.  


Market dynamics


Drivers


Compounding the drugs offers several advantages to the traditional method of prescription. Compounding chemotherapy checks the overdose or underdose of particular compounds in the market available chemotherapeutic drugs. Therefore, the ability to develop patient-specific drugs is gathering market demand for compounding chemotherapy. 


The technological advancements in the compounding of medicinal drugs to predict accurate dosage are the major driving factor. Moreover, compounding helps to make drugs allergen-free. It also allows alternative dosages to access the expired medicine. Thus, these factors are increasing the demand for compounded drugs in the market. Furthermore, the rise in the incidence of cancer and similar other diseases is to fuel the market growth.  


Restraints


There is no legal system to check the efficacy of compounded drugs. Hence, these may also prove to be harmful and even fatal if it comes out of inexperienced hands. Therefore, the uncertainty about the success rate is a major restraint to the market growth.


Lack of proper infrastructure for compounding in many pharmacies may lead to a substandard product. Moreover, Compounding under insanitary conditions causes widespread public harm. The 2012  fungal meningitis outbreak in the USA which caused 60 deaths is a reminder of the need for a proper methodology. Therefore,  compounded drugs are not FDA or any regulatory authority approved, which is a major hindrance to the compounding chemotherapy market. 


Technology analysis


Compounding chemotherapy is a method of developing chemotherapy drugs according to the patient's requirements and feasibility. This is achieved by modification or mixing of the constituents of the market-available drug brands.


Compounding is of great importance in removing compounds or colors in market brands that may be allergic to some patients. Moreover, if a child or an aged person cannot consume tablets then one can change the form by compounding to liquid syrups or injections by compounding. Therefore, compounding chemotherapy can overcome the limits of traditional chemotherapy to make health drugs more effective.  


Study objectives


This report aims to provide an in-depth analysis of the compounding chemotherapy market. The specific objectives of this market report on compounding chemotherapy are  given below:



  • To analyze and forecast the compounding chemotherapy market in terms of value and volume.

  • To provide information about the impact of covid 19 on the compounding chemotherapy market and market growth thereafter.

  • To identify the problems and prospects of the compounding chemotherapy market.

  • To give details about the technological viability of the product.

  • To provide an overview of the regional markets and potentially growing segments.

  • To highlight the key players of the industry. 


Segment overview


Segmentation of the Compounding Chemotherapy Market, by dose



  • Chemotherapeutic and

  • non-chemotherapeutics 


The chemotherapeutic segment holds the largest market share. The higher efficacy of chemotherapeutic drugs is promoting market growth. Moreover, the aging population and the increasing cancer cases are the growth boosters for this segment.  


Segmentation of the compounding chemotherapy market, by compounding type 



  • Pharmaceutical ingredient alteration (PIA)

  • Currently unavailable pharmaceutical manufacturing (CUPM)

  • Pharmaceutical dosage alteration (PDA).


Pharmaceutical dosage Alteration ( PDA) is the dominating market segment. It held about 40 % of the total market share in 2019. This is the easiest method among others and gives good effects. Moreover, less technical expertise is needed to perform PDA than other forms of modification. 


Segmentation of the Compounding Chemotherapy Market, by the delivery method



  • Gravimetric automated compounding device (weight-based)

  • Volumetric automated compounding device (volume-based) 


The Gravimetric automated compounding device (weight-based) occupies the largest market share. Easy handling of gravimetric products makes it the leading market segment. 


Segmentation of The compounding chemotherapy market, by sterility



  • Sterile

  • Non-sterile


The sterile segment holds more than 50 percent of the market share, so it is a dominating segment.  Injections and infusions that have higher efficiency need to be strictly sterile,  thereby ensuring its demand. 


Segmentation of the compounding chemotherapy market, by technology



  • With robotic arms

  • Without robotic arms


The robotic arm segment holds the major market share. Moreover, it is also having a high CAGR of 6.4 percent over the forecast period. It is due to the higher accuracy and better predictability of automated machines. 


Segmentation of the global compounding chemotherapy market, by compounder type



  • Pharmoduct

  • Equashield Pro

  • Medimix

  • Integra

  • others


The pharmoduct segment occupies the major market share. The dominance is due to its automated sterile technology and higher working efficiency.  


Segmentation of the compounding chemotherapy market, by application



  • Breast cancer

  • Blood cancer

  • Prostate cancer

  • Gastrointestinal cancer

  • Respiratory/lung cancer

  • Others


The breast cancer segment is the largest and the fastest-growing market for compounding chemotherapy. The higher prevalence of breast cancer among other types makes it the leading segment. Prostate cancer and Lung cancer follow the list in terms of market value. 


Regional analysis



  • The Americas

    • North America

      • US

      • Canada

      • Mexico



    • Latin America 





  • Europe

    • Western Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Rest of Europe



    • Eastern Europe 





  • Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Rest of Asia-Pacific 





  • Rest of the world ( RoW )

    • The Middle East




The American segment is the major regional market for the compounding chemotherapy market. The rise in the number of cancer cases and the increasing geriatric population has been pushing the growth. Moreover, better health care infrastructure and favorable government policies in this region are supporting the market growth.


Europe is the second-largest regional market of compounding chemotherapy by value. Better research facilities for compounding drugs and higher healthcare spending by the government are sustaining the growth. Moreover, the increasing geriatric population and higher disposable income of the people are expected to fuel the growth. 


The Asia Pacific is the fastest-growing segment. The rising economies of this region are better funding the healthcare sector which is driving the market growth. Moreover, rising disposable income is bringing more people under health care coverage. Furthermore, increasing literacy rate and the growth of the R&D sector in this region is to boost the market growth. 


Competitive landscape


The market for compounding chemotherapy is dominated by several global giants. The key global players are:-



  • Braun Melsungen AG

  • Pfizer Inc.

  • Baxter

  • Grifols SA

  • The Metrix Company

  • Added Pharma

  • Equashield

  • Millers Pharmacy

  • Comecer S.P.A.

  • Omnicell

  • Icon group

  • Dedalus Group

  • Arxium

  • Sterline S.R.L.

  • Loccioni 


Recent developments



  • In October 2019, Equashield, a leading provider of closed system transfer devices (CSTD), announced it would provide its service to the Netherlands, for the first time in Europe. 


Intended audience


This report will be beneficial for every stakeholder of the compounding chemotherapy market. It will help in decision making for those directly connected with the industry such as:



  • Manufacturers of chemotherapy drugs

  • Medical Research and Development Institutes

  • Hospitals and Clinics

  • Traders and Distributors

  • Patients 


Report overview


This report provides complete details on the compounding chemotherapy market in terms of current value and future forecasts. We have also identified the problems and prospects of the given market. 


The technological analysis of the product will help in knowing the product better and in decision making. Moreover, this report contains a detailed analysis of every segment of the given market for the current forecast period. This report has also highlighted the key players and the current developments in the compounding chemotherapy market. 



Report Scope:
Report Attribute/Metric Details
  Market Size   635.58 Million
  CAGR   6.04%
  Base Year   2020
  Forecast Period   2027
  Historical Data   2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors and Trends
  Segments Covered   Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, and Application
  Geographies Covered   North America, Europe, Asia-Pacific and Rest of the World (RoW)
  Key Vendors   Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni.
  Key Market Opportunities   Opioid scarcity
  Key Market Drivers

  • Technical Advances
  • Cutting-Edge Strategies\r\n


  • Speak to Analyst Ask for Customization